Advances in contezolid: novel oxazolidinone antibacterial in Gram-positive treatment
Infection · 2024
DOI: 10.1007/s15010-024-02287-w ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Infection, 2024. Verfasst von Guan-Xuan-Zi Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical School of Chinese PLA, Graduate School of Chinese, PLA General Hospital, Beijing, 100853, China. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Oxazolidinones, Gram-Positive Bacterial Infections. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Cultivation Project of PLA General Hospital for Distinguished Young Scientists, New Medicine Clinical Research Fund.
Abstract (Originalsprache)
PURPOSE: The principal objective of this project was to review and thoroughly examine the chemical characteristics, pharmacological activity, and quantification methods associated with contezolid. METHODS: The article was based on published and ongoing preclinical and clinical studies on the application of contezolid. These studies included experiments on the physicochemical properties of contezolid, in vitro antimicrobial research, in vivo antimicrobial research, and clinical trials in various phases. There were no date restrictions on these studies. RESULTS: In June 2021, contezolid was approved for treating complicated skin and soft tissue infections. The structural modification of contezolid has resulted in better efficacy compared to linezolid. It inhibits bacterial growth by preventing the production of the functional 70S initiation complex required to translate bacterial proteins. The current evidence has indicated a substantial decline in myelosuppression and monoamine oxidase inhibition without impairing its antibacterial properties. Contezolid was found to have a more significant safety profile and to be metabolised by flavin monooxygenase 5, reducing the risk of harmful effects due to drug-drug interactions. Adjusting doses is unnecessary for patients with mild to moderate renal or hepatic insufficiency. CONCLUSION: As an oral oxazolidinone antimicrobial agent, contezolid is effective against multi-drug resistant Gram-positive bacteria. The introduction of contezolid provided a new clinical option.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical School of Chinese PLA, Graduate School of Chinese, PLA General Hospital, Beijing, 100853, China.
- Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center, PLA General Hospital, 28 Fu Xing Road, Beijing, 100853, China.
- Department of Health Services, General Hospital of Central Theater Command, Wuhan, 430060, China.
- Department of Pulmonary and Critical Care Medicine, The Second Medical Center, National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, 100853, China.
- Department of Neurology, Second Medical Center of PLA General Hospital, Beijing, 100853, China.
- Medical Supplies Center, PLA General Hospital, Beijing, 100853, China.
Förderung
- National Natural Science Foundation of China
- Cultivation Project of PLA General Hospital for Distinguished Young Scientists
- New Medicine Clinical Research Fund
Zitieren
APA
Zhang, G. X., Liu, T. T., Ren, A. X., Liang, W. X., Yin, H., & Cai, Y. (2024). Advances in contezolid: novel oxazolidinone antibacterial in Gram-positive treatment. Infection. https://doi.org/10.1007/s15010-024-02287-w
Vancouver
Zhang GX, Liu TT, Ren AX, Liang WX, Yin H, Cai Y. Advances in contezolid: novel oxazolidinone antibacterial in Gram-positive treatment. Infection. 2024. doi:10.1007/s15010-024-02287-w
BibTeX
@article{Zhang2024,
author = {Zhang, Guan-Xuan-Zi and Liu, Ting-Ting and Ren, Ai-Xia and Liang, Wen-Xin and Yin, Hong and Cai, Yun},
title = {Advances in contezolid: novel oxazolidinone antibacterial in Gram-positive treatment},
journal = {Infection},
year = {2024},
doi = {10.1007/s15010-024-02287-w}
}
EUVIMED